Oxiconazole nitrate cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. Oxiconazole nitrate cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Ox...
Oxiconazole nitrate cream should be applied to affected and immediately surrounding areas once to twice daily in patients with tinea pedis, tinea corporis, or tinea cruris. Oxiconazole nitrate cream should be applied once daily in the treatment of tinea (pityriasis) versicolor. Tinea corporis, tinea cruris, and tinea (pityriasis) versicolor should be treated for 2 weeks and tinea pedis for 1 month to reduce the po...
Oxiconazole nitrate cream, 1% contains the antifungal active compound oxiconazole nitrate. This formulation is for topical dermatologic use only.
Chemically, oxiconazole nitrate is 2´,4´-dichloro-2-imidazol-1-ylacetophenone (Z)-[0-(2,4-dichlorobenzyl)oxime], mononitrate. The compound has the molecular formula C18H13ON3CI4•HNO3, a molecular weight of 492.15, and the following structural formula:
Oxiconazole nitrate is a nearly white crystalline powder, soluble in methanol; sparingly soluble in ethanol, chloroform, and acetone; and very slightly soluble in water.
Oxiconazole nitrate cream contains 10 mg of oxiconazole per gram of cream in a white to off-white, opaque cream base of purified water USP, white petrolatum USP, stearyl alcohol NF, propylene glycol USP, polysorbate 60 NF, cetyl alcohol NF, and benzoic acid USP, 0.2% as a preservative.
Pharmacokinetics: The penetration of oxiconazole nitrate into different layers of the skin was assessed using an in vitro permeation technique with human skin. Five hours after application of 2.5 mg/cm2 of oxiconazole nitrate cream onto human skin, the concentration of oxiconazole nitrate was demonstrated to be 16.2 μmol in the epidermis, 3.64 μmol in the upper corium, and 1.29 μmol in the deeper corium. Systemic absorption of oxiconazole nitrate is low. Using radiolabeled drug, less than 0.3% of the applied dose of oxiconazole nitrate was recovered in the urine of volunteer subjects up to 5 days after application of the cream formulation.
Neither in vitro nor in vivo studies have been conducted to establish relative activity between the lotion and cream formulations.
Microbiology: Oxiconazole nitrate is an imidazole derivative whose antifungal activity is derived primarily from the inhibition of ergosterol biosynthesis, which is critical for cellular membrane integrity. It has in vitro activity against a wide range of pathogenic fungi.
Oxiconazole has been shown to be active against most strains of the following organisms both in vitro and in clinical infections at indicated body sites (see INDICATIONS AND USAGE):
The following in vitro data are available; however, their clinical significance is unknown. Oxiconazole exhibits satisfactory in vitro minimum inhibitory concentrations (MICs) against most strains of the following organisms; however, the safety and efficacy of oxiconazole in treating clinical infections due to these organisms have not been established in adequate and well-controlled clinical trials:
Oxiconazole nitrate cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. Oxiconazole nitrate cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES).
Oxiconazole nitrate cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which oxiconazole nitrate cream has been shown to be effective rarely occur in children below the age of 12.
Oxiconazole nitrate cream is contraindicated in individuals who have shown hypersensitivity to any of their components.
Oxiconazole nitrate cream, 1% is not for ophthalmic or intravaginal use.
General: Oxiconazole nitrate cream is for external dermal use only. Avoid introduction of oxiconazole nitrate cream into the eyes or vagina. If a reaction suggesting sensitivity or chemical irritation should occur with the use of oxiconazole nitrate cream, treatment should be discontinued and appropriate therapy instituted. If signs of epidermal irritation should occur, the drug should be discontinued.
Information for Patients: The patient should be instructed to:
Drug Interactions: Potential drug interactions between oxiconazole nitrate and other drugs have not been systematically evaluated.
Carcinogenesis, Mutagenesis, Impairment of Fertility: Although no long-term studies in animals have been performed to evaluate carcinogenic potential, no evidence of mutagenic effect was found in 2 mutation assays (Ames test and Chinese hamster V79 in vitro cell mutation assay) or in 2 cytogenetic assays (human peripheral blood lymphocyte in vitro chromosome aberration assay and in vivo micronucleus assay in mice).
Reproductive studies revealed no impairment of fertility in rats at oral doses of 3 mg/kg/day in females (1 time the human dose based on mg/m2) and 15 mg/kg/day in males (4 times the human dose based on mg/m2). However, at doses above this level, the following effects were observed: a reduction in the fertility parameters of males and females, a reduction in the number of sperm in vaginal smears, extended estrous cycle, and a decrease in mating frequency.
Pregnancy: Teratogenic Effects: Pregnancy Category B.
Reproduction studies have been performed in rabbits, rats, and mice at oral doses up to 100, 150, and 200 mg/kg/day (57, 40, and 27 times the human dose based on mg/m2), respectively, and revealed no evidence of harm to the fetus due to oxiconazole nitrate. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing Mothers: Because oxiconazole is excreted in human milk, caution should be exercised when the drug is administered to a nursing woman.
Pediatric Use: Oxiconazole nitrate cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which oxiconazole nitrate cream has been shown to be effective rarely occur in children below the age of 12.
Geriatric Use: A limited number of patients at or above 60 years of age (n ~ 396) have been treated with oxiconazole nitrate cream in US and non-US clinical trials. The number of patients is too small to permit separate analysis of efficacy and safety. The adverse reactions reported with oxiconazole nitrate cream in this population were similar to those reported by younger patients. Based on available data, no adjustment of dosage of oxiconazole nitrate cream in geriatric patients is warranted.
During clinical trials, of 955 patients treated with oxiconazole nitrate cream, 1%, 41 (4.3%) reported adverse reactions thought to be related to drug therapy. These reactions included pruritus (1.6%); burning (1.4%); irritation and allergic contact dermatitis (0.4% each); folliculitis (0.3%); erythema (0.2%); and papules, fissure, maceration, rash, stinging, and nodules (0.1% each).
When 5% oxiconazole cream (5 times the concentration of the marketed product) was applied at a rate of 1 g/kg to approximately 10% of body surface area of a group of 40 male and female rats for 35 days, 3 deaths and severe dermal inflammation were reported. No overdoses in humans have been reported with use of oxiconazole nitrate cream.
Oxiconazole nitrate cream should be applied to affected and immediately surrounding areas once to twice daily in patients with tinea pedis, tinea corporis, or tinea cruris. Oxiconazole nitrate cream should be applied once daily in the treatment of tinea (pityriasis) versicolor. Tinea corporis, tinea cruris, and tinea (pityriasis) versicolor should be treated for 2 weeks and tinea pedis for 1 month to reduce the possibility of recurrence. If a patient shows no clinical improvement after the treatment period, the diagnosis should be reviewed.
Note: Tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk that may extend to the neck, arms, and upper thighs. Treatment of the infection may not immediately result in restoration of pigment to the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental sun exposure. Although tinea (pityriasis) versicolor is not contagious, it may recur because the organism that causes the disease is part of the normal skin flora.
The following definitions were applied to the clinical and microbiological outcomes in patients enrolled in the clinical trials that form the basis for the approval of oxiconazole nitrate cream.
Definitions:
Tinea Pedis: THERE ARE NO HEAD-TO-HEAD COMPAR ISON TRIALS OF THE OXICONAZOLE NITRATE CREAM AND LOTION FORMULATIONS IN THE TREATMENT OF TINEA PEDIS.
The two pivotal trials for the oxiconazole nitrate cream formulation involved 281 evaluable patients (total from both trials) with clinically and microbiologically established tinea pedis.
The combined results of these 2 clinical trials at the 2-week post-treatment follow-up visit are shown in the following table:
Patient Outcome | Oxiconazole Nitrate Cream | Vehicle | |
b.i.d. | q.d. | ||
Mycological cure | 77% | 79% | 33% |
Treatment success | 52% | 43% | 14% |
All the improvement and cure rates of the b.i.d.- and q.d.- treated groups did not differ significantly (95% confidence interval) from each other but were statistically (95% confidence interval) superior to the vehicle-treated group.
In addition, pediatric data (95 children ages 10 and under) available with the cream formulation indicate that it is safe and effective for use in children when used as directed. Adverse events were reported in 2 children; 1 child was reported to have reddening of the skin and 1 child was reported to have eczema-like skin alterations.
Tinea (pityriasis) Versicolor: Two pivotal clinical trials of oxiconazole nitrate cream in tinea (pityriasis) versicolor involved 219 evaluable patients in the q day oxiconazole nitrate and vehicle arms of the trial with clinical and mycological evidence of tinea (pityriasis) versicolor. Patients were treated for 2 weeks with oxiconazole nitrate cream once daily, or with cream vehicle. The combined results of these clinical trials at the 2-week post-treatment follow-up visit are shown in the following table. These results are based on 207 patients (110 in the oxiconazole nitrate group and 97 in the vehicle group) with efficacy evaluations at this visit.
Patient Outcome | Oxiconazole Nitrate Cream | Vehicle |
q.d. | ||
Mycological cure | 88% | 67% |
Treatment success | 83% | 62% |
Only once a day was shown in both studies to be statistically superior to vehicle for all efficacy parameters at 2 weeks and follow-up.
Oxiconazole nitrate cream, 1% is supplied in:
Store between 15° and 30°C (59° and 86°F).
E. FOUGERA & CO.
A division of
Fougera
PHARMACEUTICALS INC.
Melville, New York 11747
46144436A
R09/14
#316
NDC 0168-0358-30
OXICONAZOLE
NITRATE CREAM, 1%*
*Potency expressed as oxiconazole.
For Topical Dermatologic Use ONLY -
Not for Ophthalmic or Intravaginal Use.
Rx Only
NET WT 30 grams
NDC 0168-0358-30
Rx Only
OXICONAZOLE NITRATE CREAM, 1%*
*Potency expressed as oxiconazole.
For Topical Dermatologic Use ONLY -
Not for Ophthalmic or Intravaginal Use.
NET WT 30 grams
| Class | Version | Type | Effective |
|---|---|---|---|
| OXICONAZOLE Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Resource | Code type | Value | Equivalent identifiers | Source image |
|---|---|---|---|---|
| Barcode | EAN-13 | 0301680358307 | GTIN-13: 0301680358307 EAN-13: 0301680358307 GTIN-12: 301680358307 UPC-A: 301680358307 GTIN storage (14 digits): 00301680358307 | oxiconazole-03.jpg |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| c6f86816-7da6-43ea-8c25-ac9758311cc5 | Product name | 1 | 20220118 |
| 252e11b6-1a9a-4283-a242-df2c129c496d | Product name | 3 | 20170717 |
| 04b740be-5bee-4b15-ac6d-f6699e2f435d | Product name | 1 | 20160414 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0168-0358-30 | Oxiconazole Nitrate | 30 g in 1 TUBE | CREAM | 30 | 5 | |
| 0168-0358-60 | Oxiconazole Nitrate | 60 g in 1 TUBE | CREAM | 60 | 5 | |
| 0168-0358-90 | Oxiconazole Nitrate | 90 g in 1 TUBE | CREAM | 90 | 5 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0168-0358-30 | GM - Gram | 0168-0358 | eac06d55-e914-4b99-8a1f-3d8a8c0e859e | 1 | 2016-04-04 |
| 0168-0358-60 | GM - Gram | 0168-0358 | ebf50991-f79f-4115-8da3-8b5303f655df | 1 | 2016-04-04 |
| 0168-0358-90 | GM - Gram | 0168-0358 | 2a4c782b-647f-477b-877c-bfe946e9aee6 | 1 | 2016-04-04 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 0168-0358 | 0168-0358-30, 0168-0358-60, 0168-0358-90 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| OXICONAZOLE NITRATE | RQ8UL4C17S | ACTIM |
| WATER | 059QF0KO0R | IACT |
| PETROLATUM | 4T6H12BN9U | IACT |
| STEARYL ALCOHOL | 2KR89I4H1Y | IACT |
| PROPYLENE GLYCOL | 6DC9Q167V3 | IACT |
| POLYSORBATE 60 | CAL22UVI4M | IACT |
| CETYL ALCOHOL | 936JST6JCN | IACT |
| BENZOIC ACID | 8SKN0B0MIM | IACT |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N019828-001 | OXISTAT | OXICONAZOLE NITRATE | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 |
| Application-product | TE code |
|---|---|
| N019828-001 | AB |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | N019828-001 | OXISTAT | EQ 1% BASE | CREAM / TOPICAL | AB | RLD, RS | 1988-12-30 | f41ea6bd6efb… |
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | N019828-001 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | N019828-001 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | N019828-001 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N019828-001 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | N019828-001 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N019828-001 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N019828-001 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N019828-001 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | N019828-001 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | N019828-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | N019828-001 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | N019828-001 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | N019828-001 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | N019828-001 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | N019828-001 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | N019828-001 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | N019828-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | N019828-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | N019828-001 | AB | 1 | 4b0b4de00fa7… |
| 2019-12-13 00:20 UTC | 2019-12 | N019828-001 | AB | 1 | 74a2ff9319b5… |
| 2022-03-09 01:35 UTC | 2022-03 | N019828-001 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | N019828-001 | AB | 1 | 782e0a99824c… |
| 2021-05-05 16:15 UTC · 3 captures of this ZIP | 2021-05 | N019828-001 | AB | 1 | 87673890dc5c… |
| 2021-03-12 10:30 UTC | 2021-03 | N019828-001 | AB | 1 | 5aa47cf7b7d7… |
| 2020-12-22 03:56 UTC | 2020-12 | N019828-001 | AB | 1 | 8869cabd3fbd… |
| 2020-11-12 02:37 UTC | 2020-11 | N019828-001 | AB | 1 | c0c555d07b60… |
| 2019-12-14 00:12 UTC | 2019-12 | N019828-001 | AB | 1 | 3f01610625f2… |
| 2019-09-15 20:21 UTC | 2019-09 | N019828-001 | AB | 1 | b00525d2431f… |
| 2019-07-19 19:46 UTC | 2019-07 | N019828-001 | AB | 1 | ea99ee380514… |
| 2024-03-16 18:09 UTC · 4 captures of this ZIP | 2024-03 | N019828-001 | AB | 1 | 6a51e52b5d6a… |
| 2024-02-18 07:12 UTC | 2024-02 | N019828-001 | AB | 1 | 1c564ffb4f44… |
| 2023-12-20 04:57 UTC | 2023-12 | N019828-001 | AB | 1 | ea1830bbd6c7… |
| 2023-11-28 05:40 UTC · 2 captures of this ZIP | 2023-11 | N019828-001 | AB | 1 | a72a2bbeb626… |
| 2023-10-25 00:34 UTC · 2 captures of this ZIP | 2023-10 | N019828-001 | AB | 1 | 9b2671bbb829… |
| 2023-07-15 15:27 UTC · 2 captures of this ZIP | 2023-07 | N019828-001 | AB | 1 | a67488948f0b… |
| 2023-06-13 01:57 UTC · 3 captures of this ZIP | 2023-06 | N019828-001 | AB | 1 | 3f0d92c62455… |
| 2023-05-13 08:27 UTC | 2023-05 | N019828-001 | AB | 1 | 053a50430f4f… |
| 2023-01-26 05:58 UTC | 2023-01 | N019828-001 | AB | 1 | 3bdfa0b2c4d7… |
| 2022-11-12 20:34 UTC · 5 captures of this ZIP | 2022-11 | N019828-001 | AB | 1 | 3a93d1ddd44b… |
| 2022-10-28 04:53 UTC | 2022-10 | N019828-001 | AB | 1 | f41ea6bd6efb… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Oxiconazole Nitrate | OXICONAZOLE NITRATE | E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC | aa368d2b-a5d2-49dd-86e1-5693b68b46f4 | 2026-01-28 | Warnings, Adverse reactions | 0168-0358-30 0168-0358-60 0168-0358-90 0168-0358 00168035890 00168035830 00168035860 413f9391-fa2d-4449-b25d-fd11376f231e aa368d2b-a5d2-49dd-86e1-5693b68b46f4 |
Adverse event summaries are temporarily unavailable. Other product information remains available.